MUC1, a transmembrane glycoprotein, is minimally expressed and heavily glycosylated in normal tissues but aberrantly overexpressed and hypoglycosylated in epithelial tumors such as pancreatic cancer, exposing tumor-specific epitopes and making it an ideal target for immunotherapy (7, 8). This evidence concerns the gene MUC1 and familial pancreatic carcinoma.